152 related items for PubMed ID: 17542337
21. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis.
Li HY, Zhang X, Zhou T, Zhong Z, Zhong H.
BMC Nephrol; 2019 Oct 23; 20(1):384. PubMed ID: 31646979
[Abstract] [Full Text] [Related]
22. Cyclosporine dose adjustment using levels obtained six hours after the morning dose: effect on side effects in patients with autoimmune diseases.
Cantarovich M, Deschênes J.
Am J Nephrol; 1997 Oct 23; 17(5):450-7. PubMed ID: 9382165
[Abstract] [Full Text] [Related]
23. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J, Ehrich JH, Querfeld U.
Nephrol Dial Transplant; 2012 May 23; 27(5):1970-8. PubMed ID: 21976740
[Abstract] [Full Text] [Related]
24. [Effect of cyclosporin A on renal function in patients with glomerulonephritis].
Heering P, Schneider A, Grabensee B, Plum J.
Dtsch Med Wochenschr; 2001 Oct 05; 126(40):1093-8. PubMed ID: 11588659
[Abstract] [Full Text] [Related]
25. Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety.
Yu X, Ruan L, Qu Z, Cui Z, Zhang Y, Wang X, Meng L, Liu X, Wang F, Zhang Y, Liu G, Yang L.
Ren Fail; 2017 Nov 05; 39(1):688-697. PubMed ID: 28882100
[Abstract] [Full Text] [Related]
26. Long-term Cyclosporine A (Sandimmun) therapy for steroid resistant nephrotic syndrome in children.
Sancewicz-Pach K, Słowiaczek E, Kwinta-Rybicka J, Wilkosz K, Drozdz D, Nowak J.
Przegl Lek; 1996 Nov 05; 53(4):365-8. PubMed ID: 8711193
[Abstract] [Full Text] [Related]
27. Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome.
Kano K, Kyo K, Yamada Y, Ito S, Ando T, Arisaka O.
Clin Nephrol; 1999 Jul 05; 52(1):19-24. PubMed ID: 10442491
[Abstract] [Full Text] [Related]
28. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study.
Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Garcia EI, Alonso JC, Gascó JM, Pou L, Piera L.
Nephrol Dial Transplant; 2007 May 05; 22(5):1351-60. PubMed ID: 17311833
[Abstract] [Full Text] [Related]
29. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M.
J Nephrol; 2011 May 05; 24(5):613-8. PubMed ID: 21240873
[Abstract] [Full Text] [Related]
30. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study.
Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F.
Clin Ther; 2004 Sep 05; 26(9):1411-8. PubMed ID: 15531003
[Abstract] [Full Text] [Related]
31. [The treatment of nephrotic-type chronic glomerulonephritis with Sandimmun (cyclosporin A)].
Mukhin NA, Tareeva IE, Krasnova TN, Shilov EM, Miroshnichenko NG.
Ter Arkh; 1995 Sep 05; 67(8):13-5. PubMed ID: 7482320
[Abstract] [Full Text] [Related]
32. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration.
Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, Shimizu T, Kaneko K.
Pediatr Nephrol; 2011 Mar 05; 26(3):479-83. PubMed ID: 21174219
[Abstract] [Full Text] [Related]
33. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, Stefanidis I, Vargemezis V, Vlachojannis JG, Siamopoulos KC.
Am J Nephrol; 2007 Mar 05; 27(3):226-31. PubMed ID: 17389782
[Abstract] [Full Text] [Related]
34. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial.
Hoyer PF, Brodeh J.
J Am Soc Nephrol; 2006 Apr 05; 17(4):1151-7. PubMed ID: 16540560
[Abstract] [Full Text] [Related]
35. Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.
Sijpkens YW, Mallat MJ, Siegert CE, Zwinderman AH, Westendorp RG, de Fijter JW, van Es LA, Paul LC.
Clin Nephrol; 2001 Feb 05; 55(2):149-55. PubMed ID: 11269679
[Abstract] [Full Text] [Related]
36. What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy?
Goumenos DS.
Expert Opin Pharmacother; 2008 Jul 05; 9(10):1695-704. PubMed ID: 18570603
[Abstract] [Full Text] [Related]
37. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years.
Tao JL, Liu LL, Wen YB, Gao RT, Li H, Li MX, Li XM, Li XW.
Chin Med J (Engl); 2011 Nov 05; 124(21):3490-4. PubMed ID: 22340164
[Abstract] [Full Text] [Related]
38. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T.
Clin Nephrol; 2009 Oct 05; 72(4):268-73. PubMed ID: 19825332
[Abstract] [Full Text] [Related]
39. Renal biopsy findings in children receiving long-term treatment with cyclosporine a given as a single daily dose.
Tanaka H, Tsugawa K, Suzuki K, Ito E.
Tohoku J Exp Med; 2006 Jul 05; 209(3):191-6. PubMed ID: 16778365
[Abstract] [Full Text] [Related]
40. Cyclosporine A induced histological changes of Cathepsin L and CD2AP expression in renal glomeruli and tubules.
Sugimoto K, Miyazawa T, Enya T, Miyazaki K, Okada M, Takemura T.
Clin Exp Nephrol; 2017 Feb 05; 21(1):83-91. PubMed ID: 26975192
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
